Stockreport

Valneva sells chikungunya vaccine priority review voucher for $103 mln [Reuters]

Valneva SE - American Depositary Shares  (VALN) 
PDF Food and Drug Administration (FDA) for $103 million. Valneva was awarded a tropical disease PRV in November 2023 for IXCHIQ, its single-dose vaccine for the prevention [Read more]